They verified that only prostate cancers expressing both PSCA and PSMA antigens are destroyed by these modified T cells, while single-antigen-positive tumours are not [93], ensuring enhanced specificity and safety in CAR-T cell activation. The gene discussed is FOLH1; the disease is Familial prostate cancer.